Nuclear factor erythroid 2–related factor 2–antioxidant response element signaling pathway (Nrf2–ARE signaling pathway)

The **Nrf2–ARE signaling pathway** centers on the transcription factor **Nuclear factor erythroid 2–related factor 2 (Nrf2)**, encoded by the NFE2L2 gene, which translocates to the nucleus under oxidative or electrophilic stress and binds to **antioxidant response elements (ARE)** within the promoters of target genes[1][5]. Activation of this pathway leads to the transcription of a battery of cytoprotective and detoxification genes, notably those encoding phase II enzymes such as NQO1, HO-1, and glutathione biosynthesis enzymes, crucial for neutralizing reactive oxygen species (ROS) and maintaining cellular redox homeostasis[1][3][7]. Nrf2 is negatively regulated by Keap1, which sequesters and targets it for ubiquitin-mediated degradation under basal conditions; during oxidative stress, this inhibition is relieved, allowing Nrf2 activation[1][7]. The Nrf2–ARE axis is a major cellular defense mechanism against oxidative damage and inflammation and is implicated in multiple physiological and pathological processes, including neuroprotection, carcinogenesis, and immune modulation[1][4][3][7]. Therapeutically, the pathway is targeted for diseases characterized by oxidative stress and chronic inflammation, including cancer, neurodegeneration (Alzheimer’s, Parkinson’s, ALS), cardiovascular disease, and chronic inflammatory disorders; various small molecules and dietary compounds can pharmacologically activate the pathway[2][3][4][7]. However, persistent pathway activation can undermine cancer therapy efficacy and drive tumor progression, presenting both promise and challenge for its clinical modulation[7][4][3].

Other names

Nrf2–ARE pathwayNRF2–ARE pathwayNFE2L2–ARE pathwayNrf2 signaling pathway

- Small-molecule activation of Nrf2 nuclear translocation by disrupting Keap1–Nrf2 interaction - Protein stabilization of Nrf2 - Upregulation of ARE-driven antioxidant and detoxification genes - Enhancement of cellular antioxidant capacity - Inhibition of Nrf2 ubiquitination and proteasomal degradation